DexCom (DXCM) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting started.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature businesses, exhibiting fairly steady performance from quarter to quarter.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Dexcom Stock A Buy Now?
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past.
S&P 500 Gains and Losses Today: Amazon Stock Surges as Cloud Business Boosts Earnings; DexCom Drops
Shares of an e-commerce and cloud computing powerhouse delivered big gains on the final day of October, while a medical device maker came under pressure after an executive provided an underwhelming outlook for 2026 sales growth.
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.
DexCom Stock Is the Worst Performer in the S&P 500. Here's Why.
The maker of diabetes technology posts better-than-expected revenue but shares are falling.
Dexcom shares extend fall over 2026 growth concerns
Dexcom shares tumbled 12% in premarket trading on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.
